Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Positions To Dominate In Vaccines; Will The Bet Pay Off?

Executive Summary

The British pharma outlined its strategy for winning as one of the world’s leading vaccines makers May 6, two months after completing the acquisition of Novartis’ vaccines business.

You may also be interested in...



For GSK, Lots Of Drugs In R&D, But Many Are Long-Term

GlaxoSmithKline PLC held an expansive R&D update Nov. 3, laying out a strategy to file up to 20 drugs with regulators before 2020, seven of which could launch in that timeline. But few investors are likely to walk away from the four-hour meeting with a changed sentiment on the firm in the near-term, where it is facing strong headwinds from slowing sales of its top-seller Advair Diskus.

Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall

FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.

Swapping Assets Now Down To Execution For GSK And Novartis

Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel